Korean J Urogenit Tract Infect Inflamm.  2014 Apr;9(1):9-13. 10.14777/kjutii.2014.9.1.9.

Non-Antibiotic Prophylaxis for Recurrent Urinary Tract Infections

• Kim KH

• KMID: 1921570
• DOI: http://doi.org/10.14777/kjutii.2014.9.1.9

Abstract

Urinary tract infections (UTI) are one of the most common infections affecting women. In a recent study of college women with their first UTI, 27% experienced at least one culture-confirmed recurrence within the six months following the initial infection and 2.7% had a second recurrence during this time period. Women with recurrent UTI have an increased susceptibility to vaginal colonization with uropathogens due to a greater propensity for them to adhere to their epithelial cells. Risk factors include frequent sexual intercourse, spermicide use, first UTI at an early age, and maternal history of UTI. Effectiveness of continuous or post-coital prophylaxis with low-dose antimicrobials or intermittent self-treatment with antimicrobials in management of recurrent uncomplicated UTIs in women has been demonstrated. However, antibiotics are the main driving force in development of antibiotic resistance and can lead to resistance of not only the causative microorganisms, but also the commensal flora. The increasing prevalence of Escherichia coli isolates (the most prevalent uropathogen) that are resistant to antimicrobial agents has stimulated interest in non-antibiotic methods for prevention of UTIs. We discuss the overall use of non-antibiotic methods for prevention of recurrent UTI, including the use of immunostimulant OM-89, a vaginal vaccine or estrogen, lactobacilli prophylaxis, and cranberry.

Keyword

Urinary tract infections; Prevention and control; Recurrence; Immunosuppressive agents; Dietary supplements

MeSH Terms

Anti-Bacterial Agents
Anti-Infective Agents
Coitus
Colon
Dietary Supplements
Drug Resistance, Microbial
Epithelial Cells
Escherichia coli
Estrogens
Female
Humans
Immunosuppressive Agents
Prevalence
Recurrence
Risk Factors
Urinary Tract Infections*
Vaccinium macrocarpon
Anti-Bacterial Agents
Anti-Infective Agents
Estrogens
Immunosuppressive Agents

Reference

1. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993; 329:1328–34.

2. Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000; 182:1177–82.

3. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninfe-riority trial in postmenopausal women. Arch Intern Med. 2012; 172:704–12.

4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21:335–76.

5. Bäckhed F, Söderhäll M, Ekman P, Normark S, Richter-Dahlfors A. Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. Cell Microbiol. 2001; 3:153–8.

6. Huber M, Krauter K, Winkelmann G, Bauer HW, Rahlfs VW, Lauener PA, et al. Immunostimulation by bacterial components: II. Efficacy studies and metaanalysis of the bacterial extract OM-89. Int J Immunopharmacol. 2000; 22:1103–11.

7. Tammen H. Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group. Br J Urol. 1990; 65:6–9.

8. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a metaanalysis. Int J Antimicrob Agents. 2009; 33:111–9.

9. Lee SJ, Kim SJ, Cho YH, Woo YN, Kim BW, Kim YS, et al. Efficacy and safety of Uro-Vaxom treatment for patients with recurrent cystitis: an open multicenter study. Korean J Urol. 2007; 48:428–32.

10. Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC. Multicenter UTI Study Group. A longterm, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005; 47:542–8. discussion 8.

11. Ha US, Cho YH. Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. Int J Antimicrob Agents. 2008; 31(Suppl 1):S63–7.

12. Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007; 177:1349–53. quiz 591.

13. Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003; 170:867–9.

14. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993; 329:753–6.

15. Kirkengen AL, Andersen P, Gjers⊘e E, Johannessen GR, Johnsen N, Bodd E. Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Care. 1992; 10:139–42.

16. Cardozo L, Benness C, Abbott D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. Br J Obstet Gynaecol. 1998; 105:403–7.

17. Baerheim A, Larsen E, Digranes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care. 1994; 12:239–43.

18. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291:1701–12.

19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605–13.

20. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011; 5:316–22.

21. Reid G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr. 2001; 73(2 Suppl):437S–443S.

22. Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol. 1999; 65:3763–6.

23. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011; 52:1212–7.

24. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ. 2001; 322:1571.

25. Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010; 10:94.

26. Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios. 1988; 55:173–81.

27. Zafriri D, Ofek I, Adar R, Pocino M, Sharon N. Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells. Antimicrob Agents Chemother. 1989; 33:92–8.

28. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithe-lial-cell surfaces by proanthocyanidin extracts from cranberries. N Engl J Med. 1998; 339:1085–6.

29. Ofek I, Goldhar J, Zafriri D, Lis H, Adar R, Sharon N. Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med. 1991; 324:1599.

30. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012; 10:CD001321.

31. Guay DR. Cranberry and urinary tract infections. Drugs. 2009; 69:775–807.

32. Albrecht U, Goos KH, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armora-ciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007; 23:2415–22.

33. Alraek T, Soedal LI, Fagerheim SU, Digranes A, Baerheim A. Acupuncture treatment in the prevention of uncomplicated recurrent lower urinary tract infections in adult women. Am J Public Health. 2002; 92:1609–11.

34. Aune A, Alraek T, LiHua H, Baerheim A. Acupuncture in the prophylaxis of recurrent lower urinary tract infection in adult women. Scand J Prim Health Care. 1998; 16:37–9.